Article

Real‐world implementation of DPYD and UGT1A1 pharmacogenetic testing in a community‐based cancer center

2024-01-26

Abstract excerpt

Abstract We set out to demonstrate the feasibility of pharmacogenetic testing of DPYD and UGT1A1 and explore the clinical benefits in a community‐based cancer center. We conducted a retrospective review of 280 patients who underwent pharmacogenetic testing between November 2020 and May 2023. The primary end points included the percentage of patients with results prior to chemotherapy initiation, percentage of DPYD...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 137883ab-817f-58fd-a451-c3500b17c513
DOI: 10.1111/cts.13704

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Real‐world implementation of DPYD and UGT1A1 pharmacogenetic testing in a community‐based cancer centerDOI 10.1111/cts.13704Read

Ten-year experience with pharmacogenetic testing for DPYD in a national cancer center in Italy: Lessons learned on the path to implementationSemantic proximity Read

Addressing barriers to increased adoption of DPYD genotyping at a large multisite cancer center.Semantic proximity Read

Pharmacogenetic-guided dosing for fluoropyrimidine (DPYD) and irinotecan (UGT1A1*28) chemotherapies for patients with cancer (PACIFIC-PGx): A multicenter clinical trial.Semantic proximity Read

Strategies for DPYD Testing Prior to Fluoropyrimidine Chemotherapy in the United StatesSemantic proximity Read

Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.Semantic proximity Read

A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical PracticeSemantic proximity Read

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.Semantic proximity Read

Impact of Upfront DPYD Genotyping on Fluoropyrimidine Adjuvant Therapy in Colorectal Cancer: A Real-World Data.Semantic proximity Read

Implementation and clinical benefit of DPYD genotyping in a Danish cancer population.Semantic proximity Read

Importance of and Strategies for Implementing DPYD Testing to Prevent Severe Fluoropyrimidine Chemotherapy Toxicity in Health Care Systems.Semantic proximity Read

Real-World Impact of an In-House Dihydropyrimidine Dehydrogenase (DPYD) Genotype Test on Fluoropyrimidine Dosing, Toxicities, and Hospitalizations at a Multisite Cancer Center.Semantic proximity Read

CLINICAL OPPORTUNITIES FOR GERMLINE PHARMACOGENETICS AND MANAGEMENT OF DRUG-DRUG INTERACTIONS IN PATIENTS WITH ADVANCED SOLID CANCERSSemantic proximity Read